Scholar Rock
Scholar Rock
SRRK
NASDAQ
34.62
USD
-3.27%
About
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor.
Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA).
Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 509.1K |
| Three Month Average Volume | 17.3M |
| High Low | |
| Fifty-Two Week High | 21.17 USD |
| Fifty-Two Week Low | 5.94 USD |
| Fifty-Two Week High Date | 28 Dec 2023 |
| Fifty-Two Week Low Date | 18 Sep 2023 |
| Price and Volume | |
| Current Price | 9.3 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.07% |
| Thirteen Week Relative Price Change | -7.46% |
| Twenty-Six Week Relative Price Change | -46.06% |
| Fifty-Two Week Relative Price Change | 18.75% |
| Year-to-Date Relative Price Change | -58.23% |
| Price Change | |
| One Day Price Change | -0.21% |
| Thirteen Week Price Change | -0.96% |
| Twenty-Six Week Price Change | -40.69% |
| Five Day Price Change | 0.32% |
| Fifty-Two Week Price Change | 48.80% |
| Year-to-Date Price Change | -50.53% |
| Month-to-Date Price Change | 2.42% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.96419 USD |
| Book Value Per Share (Most Recent Quarter) | 1.67042 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.96419 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.67042 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.26169 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.98914 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.21847 USD |
| Normalized (Last Fiscal Year) | -1.98914 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.98914 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.21847 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.98914 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.21847 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.68439 USD |
| Cash Per Share (Most Recent Quarter) | 2.38141 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.95502 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.19863 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.84136 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -616 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -647.95% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -656.40% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -647.95% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -6.13% |
| Tangible Book Value (5 Year) | 16.13% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -45.61% |
| Total Debt (5 Year) | 155.21% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -27.67% |
| EPS Change (Trailing Twelve Months) | -10.53% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -140,421,000 |
| Net Debt (Last Fiscal Year) | -229,920,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 22 |
| Long Term Debt to Equity (Most Recent Quarter) | 36 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -145,297,000 |
| Free Cash Flow (Trailing Twelve Months) | -168,648,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 22 |
| Total Debt to Equity (Most Recent Quarter) | 37 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.55% |
| Return on Assets (Trailing Twelve Months) | -79.66% |
| Return on Assets (5 Year) | -38.14% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -68.30% |
| Return on Equity (Trailing Twelve Months) | -121.29% |
| Return on Equity (5 Year) | -58.60% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -55.26% |
| Return on Investment (Trailing Twelve Months) | -89.70% |
| Return on Investment (5 Year) | -44.31% |